Patents by Inventor Micah Benson
Micah Benson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11912987Abstract: This invention describes a novel CRISPR/Cas9 target identification platform permitting the discovery of novel genes and pathways involved in the ability of T cells and NK cells to react against and generate an anti-tumor response.Type: GrantFiled: June 24, 2021Date of Patent: February 27, 2024Assignee: KSQ Therapeutics, Inc.Inventor: Micah Benson
-
Publication number: 20230340411Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: December 13, 2022Publication date: October 26, 2023Applicant: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason J. Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael R. Schlabach, Noah Jacob Tubo, James Martin Kaberna, II
-
Publication number: 20230220380Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: December 13, 2022Publication date: July 13, 2023Applicant: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason J. Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael R. Schlabach, Noah Jacob Tubo
-
Publication number: 20230108584Abstract: Methods for activating and expanding TILs using unconventional cytokines are provided. These methods include techniques for activating and expanding TILs using streamlined approaches, including one-step approaches, approaches using agonists for stimulation, approaches more suitable for clinical manufacturing, and approaches without the requirement of feeder cells, are provided. Compositions of expanded populations of TILs are also provided, in addition to populations of expanded TILs enriched in central memory T cell phenotype.Type: ApplicationFiled: February 26, 2021Publication date: April 6, 2023Applicant: KSQ Therapeutics, Inc,Inventors: Micah Benson, Noah Jacob Tubo, Nicholas John Colletti, Robert Andrew LaMothe, Gregory V. Kryukov, Michael R. Schlabach, Sean Philip Leary Arlauckas
-
Publication number: 20230088186Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: August 25, 2022Publication date: March 23, 2023Applicant: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason J. Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael R. Schlabach, Noah Jacob Tubo
-
Patent number: 11608500Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: GrantFiled: June 9, 2022Date of Patent: March 21, 2023Assignee: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason J. Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael R. Schlabach, Noah Jacob Tubo
-
Publication number: 20220315921Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: June 9, 2022Publication date: October 6, 2022Applicant: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason J. Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael R. Schlabach, Noah Jacob Tubo
-
Patent number: 11459544Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: GrantFiled: March 29, 2022Date of Patent: October 4, 2022Assignee: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason J. Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael R. Schlabach, Noah Jacob Tubo, James Martin Kaberna, II
-
Publication number: 20220267727Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: March 29, 2022Publication date: August 25, 2022Applicant: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason J. Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael R. Schlabach, Noah Jacob Tubo, James Martin Kaberna, II
-
Patent number: 11421228Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: GrantFiled: June 24, 2021Date of Patent: August 23, 2022Assignee: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason J. Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael R. Schlabach, Noah Jacob Tubo
-
Publication number: 20220220442Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: March 29, 2022Publication date: July 14, 2022Applicant: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason J. Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael R. Schlabach, Noah Jacob Tubo, James Martin Kaberna, II
-
Publication number: 20220154178Abstract: This invention describes a novel CRISPR/Cas9 target identification platform permitting the discovery of novel genes and pathways involved in the ability of T cells and NK cells to react against and generate an anti-tumor response.Type: ApplicationFiled: June 24, 2021Publication date: May 19, 2022Applicant: KSQ Therapeutics, Inc.Inventor: Micah Benson
-
Patent number: 11332713Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: GrantFiled: November 18, 2020Date of Patent: May 17, 2022Assignee: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael Schlabach, Noah Tubo, James Martin Kaberna, II
-
Patent number: 11261428Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: GrantFiled: March 14, 2019Date of Patent: March 1, 2022Assignee: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael Schlabach, Noah Tubo, James Martin Kaberna, II
-
Publication number: 20220041713Abstract: Methods and compounds for conferring site-specific or local immune privilege.Type: ApplicationFiled: September 18, 2019Publication date: February 10, 2022Inventors: Joanne L. Viney, Nathan Higginson-Scott, Micah Benson, Alan Crane, Kevin Lewis Otipoby
-
Publication number: 20220002409Abstract: Methods and compounds for conferring site-specific or local immune privilege.Type: ApplicationFiled: February 10, 2021Publication date: January 6, 2022Inventors: Joanne L. Viney, Nathan Higginson-Scott, Micah Benson, Alan Crane
-
Publication number: 20210388349Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: ApplicationFiled: June 24, 2021Publication date: December 16, 2021Applicant: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason J. Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael R. Schlabach, Noah Jacob Tubo
-
Publication number: 20210317443Abstract: This invention describes a novel CRISPR/Cas9 target identification platform permitting the discovery of novel genes and pathways involved in the ability of T cells and NK cells to react against and generate an anti-tumor response.Type: ApplicationFiled: June 24, 2021Publication date: October 14, 2021Applicant: KSQ Therapeutics, Inc.Inventor: Micah Benson
-
Patent number: 11111493Abstract: The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.Type: GrantFiled: February 14, 2020Date of Patent: September 7, 2021Assignee: KSQ Therapeutics, Inc.Inventors: Micah Benson, Jason Merkin, Gregory V. Kryukov, Solomon Martin Shenker, Michael Schlabach, Noah Tubo
-
Patent number: 11078481Abstract: This invention describes a novel CRISPR/Cas9 target identification platform permitting the discovery of novel genes and pathways involved in the ability of T cells and NK cells to react against and generate an anti-tumor response.Type: GrantFiled: August 3, 2017Date of Patent: August 3, 2021Assignee: KSQ Therapeutics, Inc.Inventor: Micah Benson